Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACB vs GMGI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

ACB Overall Winner 6-Pillar Tally: ACB 4 – 2 GMGI Matrix Metrics: ACB 5 – 5 GMGI

As of Nov 20, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Golden Matrix Group, Inc. (GMGI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACB carries a Unified Composite Score of 44.2/100 (HOLD) at $4.16 (109.9x Forward P/E, -13.8% operating margin), whereas GMGI carries 51.1/100 (HOLD) at $0.64 (128.2x Forward P/E, -0.8% operating margin).

  • Composite vs. Pillar Nuance: While GMGI currently prints a higher short-term Unified Composite Score (51.1/100 HOLD vs. ACB 44.2/100 HOLD), ACB captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. -0.8% operating margin) and revenue trajectory (-8.8% vs. +15.4% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACB vs GMGI
ACB NASDAQ Head-to-Head Winner
Aurora Cannabis Inc. Common Shares
Medicinal Chemicals & Botanical Products
$4.16
-2.35% 1D
Market Cap $280.1M
TTM Revenue $314M
Forward P/E 109.9x
Beta / 30D Vol 1.06β · 88% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 20.0 Fund 46.0 Flow 61.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $4.63 · SMA50: $4.31
GMGI NASDAQ
Golden Matrix Group, Inc. Common Stock
Services-Prepackaged Software
$0.64
+9.86% 1D
Market Cap $81.9M
TTM Revenue $179M
Forward P/E 128.2x
Beta / 30D Vol 1.40β · 117% Vol
Unified Composite Score
51.1 / 100 HOLD
Tech 60.0 Fund 45.0 Flow 50.0 Mom 38.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $0.61 · SMA50: $0.68

6-Pillar Scorecard Institutional Category Breakdown (ACB 4 – 2 GMGI)

Columns: Metric · ACB · GMGI
1. Valuation Multiples ACB
Forward P/E 109.9x 128.2x
Trailing P/E 109.9x 128.2x
PEG Ratio N/M N/M
EV / Revenue 0.8x 0.5x
2. Growth & Scale ACB
Revenue Growth (YoY) -8.8% +15.4%
Earnings Growth (YoY) -94.7% -99.6%
TTM Revenue (USD) $314M $179M
Market Cap $280.1M $81.9M
3. Profitability & Quality GMGI
Gross Margin 44.2% 56.8%
Operating Margin -13.8% -0.8%
Net Profit Margin -38.2% -3.0%
Return on Equity (ROE) -9.4% -5.0%
4. Balance Sheet & Cash Flow GMGI
Cash Generation (TTM) -$25M $12M EBITDA
Cash Flow Margin -8.1% 6.6% EBITDA Mgn
Net Cash / Leverage $44M Net Cash $0.88 Book/Sh · -5.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 321.4% (60th %ile) N/A (N/A)
Put/Call OI Skew 0.25x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ACB
OpEx & R&D Intensity 58.0% of Rev ($182M) 57.6% of Rev ($103M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Electronic Gaming & Multimedia Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACB (5) vs GMGI (5)
Institutional Metric ACB GMGI Criterion Row Edge
Market Capitalization
Scale
$280.1M $81.9M Larger Scale ACB
Trailing P/E Ratio
Valuation
109.9x 128.2x Lower Multiple ACB
Forward P/E Ratio
Valuation
109.9x 128.2x Lower Multiple ACB
Revenue Growth (YoY)
Growth
-8.8% +15.4% Higher Growth GMGI
Operating Margin (TTM)
Profitability
-13.8% -0.8% Higher Margin GMGI
Net Profit Margin
Profitability
-38.2% -3.0% Higher Margin GMGI
Return on Equity (ROE)
Capital Efficiency
-9.4% -5.0% Higher ROE GMGI
52-Week Range Position
Momentum
42% ($3–$6) 9% ($0–$2) Stronger Trend ACB
Beta / 30D Volatility
Risk Regime
1.06β · 88% Vol 1.40β · 117% Vol Lower Realized Risk ACB
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 51.1 / 100 (HOLD) Higher Composite GMGI
Trailing 12M Revenue (USD)
Operating Scale
$314M $179M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.2% 56.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$25M ($44M Net Cash) $12M EBITDA ($0.88 Book/Sh · -5.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GMGI +3.79 pp
ACB: -11.24% · GMGI: -7.45%
3M Horizon GMGI +3.48 pp
ACB: -19.17% · GMGI: -15.69%
6M Horizon ACB +10.7 pp
ACB: -13.72% · GMGI: -24.42%
1Y Horizon ACB +10.7 pp
ACB: -13.72% · GMGI: -24.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACB vs GMGI. Trailing 12-month operating profitability (ACB -13.8% vs GMGI -0.8%) and valuation multiples (ACB 109.9x vs GMGI 128.2x Forward P/E) are benchmarked directly in Pillar 4 below.

ACB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$314M
Gross Margin44.2%
Op. Margin-13.8%
ROE / Fwd P/E-9.4% · 109.9x
GMGI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$179M
Gross Margin56.8%
Op. Margin-0.8%
ROE / Fwd P/E-5.0% · 128.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACB CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 321.4%
IV Percentile 60th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GMGI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GMGI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACB Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $280.1M market capitalization and -13.8% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($182M)
90D Engineering Disclosures 0 Published
GMGI Moat Profile Cyclical / Execution-Driven Positioning
Electronic Gaming & Multimedia Operator
Competes within the Electronic Gaming & Multimedia value chain with $81.9M market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 57.6% of Rev ($103M)
90D Engineering Disclosures 0 Published

Investor FAQ ACB vs GMGI Key Questions & Quantitative Answers

As of Nov 20, 2026, Aurora Cannabis Inc. Common Shares (ACB) is the stronger overall head-to-head candidate over Golden Matrix Group, Inc. (GMGI) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ACB carries a Unified Composite Score of 44.2/100 (HOLD) at $4.16 (109.9x Forward P/E, -13.8% operating margin), whereas GMGI carries 51.1/100 (HOLD) at $0.64 (128.2x Forward P/E, -0.8% operating margin). Composite vs. Pillar Nuance: While GMGI currently prints a higher short-term Unified Composite Score (51.1/100 HOLD vs. ACB 44.2/100 HOLD), ACB captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-13.8% vs. -0.8% operating margin) and revenue trajectory (-8.8% vs. +15.4% YoY).

ACB leads the Growth & Scale pillar: ACB posts -8.8% YoY revenue growth and -94.7% YoY earnings growth on $314M TTM revenue (44.2% gross margin, -13.8% operating margin), compared with GMGI at +15.4% YoY revenue growth and -99.6% YoY earnings growth on $179M TTM revenue (56.8% gross margin, -0.8% operating margin). On trailing 12-month operating scale, ACB generates $314M in USD-normalized revenue versus $179M for GMGI. In operating R&D and SG&A reinvestment, ACB deploys 58.0% of Rev ($182M) (0 90-day corporate R&D disclosures) versus 57.6% of Rev ($103M) (0 disclosures) for GMGI.

ACB screens cheaper on headline valuation multiples. ACB trades at 109.9x Forward P/E, 109.9x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-8.1% FCF margin), whereas GMGI trades at 128.2x Forward P/E, 128.2x Trailing P/E, N/M PEG, and 0.5x EV/Revenue (6.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACB (-9.4% ROE) versus GMGI (-5.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ACB carries 321.4% implied volatility (60th %ile, Elevated (60th–80th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 88% Vol realized risk). By comparison, GMGI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.